,225 Although beyond the scope of this review, it should be noted that more progress for NOT-gate CAR NK cells has been made in hematological malignancies and a trial for CD33/FLT3-NOT-EMCN CAR NK cells (SENTI-202) in AML is currently recruiting (NCT06325748). This evidence concerns the gene FLT3 and acute myeloid leukemia.